Description
Description
There are approximately 400,000 to 1 million people with hemophilia in the world. Among them, there are about 100,000 to 200,000 patients in China. The registered hemophilia patients in China are less than 20,000, because most patients give up treatment due to the expensive medical expenses. Those who lack coagulation factor VIII account for 80% to 85% of the hemophilia A patients. Currently, there is no cure for hemophilia, treatment for which on the market are all alternatives. Coagulation factors are the main drugs.
In 1992, Baxter (Baxalta) publicized the first recombinant factor VIII(rFVIII). Because it has the same effects as natural coagulation factors without risks of blood-borne virus contamination, it is very popular in the market. The developed countries master mature technologies of recombinant coagulation factors. For example, recombinant coagulation factor VIII now has experienced four rounds of upgradation. The main manufacturers are Bayer, Baxalta, Pfizer, etc. By the end of 2020, no domestic recombinant coagulation factor VIII has been launched in China.
According to CRI’s market research, Recombinant Factor Ⅷ developed rapidly after entering China. Its annual sales increased from less than CNY 6 million in 2009 to CNY481 million in 2019, and the CAGR reached 55% in 2009 to 2019. Currently, Recombinant Factor Ⅷ sold on the Chinese market is all imported from Bayer, Baxalta and Pfizer. According to sales value, Bayer accounted for nearly 70% of the Chinese market in 2019.
CRI forecasts that with the development of China’s economy, patients with hemophilia are more able to pay medical expenses. It is expected that the market scale of Recombinant Factor Ⅷ in China will continue to increase from 2020 to 2024. After 2022, there is possibility that Chinese companies may launch Recombinant Factor Ⅷ.
Topics Covered:
-Development of Recombinant Factor Ⅷ in China
-Sales volume and value of Recombinant Factor Ⅷ in China
-Sales volume and value of Recombinant Factor Ⅷ in regions of China
-Price of Recombinant Factor Ⅷ in the Chinese market
-Key players of Recombinant Factor Ⅷ in the Chinese market
-Research progress of Chinese companies on Recombinant Factor Ⅷ
-Chinese market prospects on Recombinant Factor Ⅷ from 2020 to 2024
